# A Study in People With Idiopathic Pulmonary Fibrosis to Test Whether Pirfenidone Influences the Amount of BI 1015550 in the Blood

> **NCT06241560** · PHASE2 · RECRUITING · sponsor: **Boehringer Ingelheim** · enrollment: 20 (estimated)

## Conditions studied

- Idiopathic Pulmonary Fibrosis

## Interventions

- **DRUG:** BI 1015550
- **DRUG:** Pirfenidone

## Key facts

- **NCT ID:** NCT06241560
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-05
- **Primary completion:** 2026-08-04
- **Final completion:** 2026-08-06
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2026-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06241560

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06241560, "A Study in People With Idiopathic Pulmonary Fibrosis to Test Whether Pirfenidone Influences the Amount of BI 1015550 in the Blood". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06241560. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*